malondialdehyde has been researched along with s 1033 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Sherbiny, M; Elsherbiny, NM; Said, E | 1 |
| El-Agamy, DS | 1 |
| Said, E; Salem, HA; Samaha, MM | 1 |
3 other study(ies) available for malondialdehyde and s 1033
| Article | Year |
|---|---|
Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib.
Topics: Animals; Blood Urea Nitrogen; Collagen; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Evaluation, Preclinical; Glutathione; Hydroxyproline; Kidney; Male; Malondialdehyde; Oxidative Stress; Protein Kinase Inhibitors; Pyrimidines; Rats, Sprague-Dawley; Superoxide Dismutase; Toll-Like Receptor 4; Transcription Factor RelA | 2015 |
Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits.
Topics: Animals; Aorta; Atherosclerosis; Chemical and Drug Induced Liver Injury; Cholesterol, Dietary; Endothelium, Vascular; Hyperlipidemias; Lipids; Male; Malondialdehyde; Nitric Oxide; Plaque, Atherosclerotic; Protein-Tyrosine Kinases; Pyrimidines; Rabbits; Random Allocation; Receptor, Platelet-Derived Growth Factor beta; Vasoconstriction | 2017 |
Nilotinib enhances β-islets integrity and secretory functions in a rat model of STZ-induced diabetes mellitus.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Blood Glucose; Body Weight; Caspase 3; Catalase; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Glucagon; Glutathione; Insulin; Insulin-Secreting Cells; Male; Malondialdehyde; Organ Size; Oxidative Stress; Pyrimidines; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2019 |